Treatment of Psoriasis Using Acitretin in HIV-Positive Patients

Roche

Status and phase: Completed; Phase 3

Conditions: Psoriasis; HIV Infections

Treatments: Drug: Acitretin

Study type: Interventional

Funder types: Industry

Identifiers

NCT00002143

239A

65-93(2)

Details and patient eligibility

About

To determine the efficacy of acitretin in the treatment of psoriasis in HIV/AIDS patients.

Etretinate, a retinoid, has proven successful in the treatment of HIV-infected patients with psoriasis, but it has an elimination half-life of 100 days. Acitretin, a metabolite of etretinate, has a much shorter half-life of 2 to 3 days. Acitretin has proven effective in treating psoriasis in patients without HIV infection by reducing skin involvement and clearing of the condition, but it has not been thoroughly evaluated in HIV-infected patients.

Full description

Etretinate, a retinoid, has proven successful in the treatment of HIV-infected patients with psoriasis, but it has an elimination half-life of 100 days. Acitretin, a metabolite of etretinate, has a much shorter half-life of 2 to 3 days. Acitretin has proven effective in treating psoriasis in patients without HIV infection by reducing skin involvement and clearing of the condition, but it has not been thoroughly evaluated in HIV-infected patients.

Patients receive acitretin daily, with dose increases every 4 weeks based on quantitative assessment of the skin using the Psoriasis Area and Severity Index (PASI). Treatment continues for a total of 20 weeks. Patients are followed every 2 weeks.

Sex: All

Ages: 18 to 55 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria

Concurrent Medication:

Allowed:

• Any nondermatologic medication.

Patients must have:

• HIV infection.
• Psoriasis involving at least 10 percent of body surface.